Cargando…
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentatio...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950724/ https://www.ncbi.nlm.nih.gov/pubmed/35337057 http://dx.doi.org/10.3390/v14030650 |
_version_ | 1784675211611734016 |
---|---|
author | Cicchitto, Gaetano Cardillo, Lorena de Martinis, Claudio Sabatini, Paola Marchitiello, Rosita Abate, Giovanna Rovetti, Adele Cavallera, Antonietta Apuzzo, Camillo Ferrigno, Francesco Fusco, Giovanna |
author_facet | Cicchitto, Gaetano Cardillo, Lorena de Martinis, Claudio Sabatini, Paola Marchitiello, Rosita Abate, Giovanna Rovetti, Adele Cavallera, Antonietta Apuzzo, Camillo Ferrigno, Francesco Fusco, Giovanna |
author_sort | Cicchitto, Gaetano |
collection | PubMed |
description | There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations. |
format | Online Article Text |
id | pubmed-8950724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89507242022-03-26 Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant Cicchitto, Gaetano Cardillo, Lorena de Martinis, Claudio Sabatini, Paola Marchitiello, Rosita Abate, Giovanna Rovetti, Adele Cavallera, Antonietta Apuzzo, Camillo Ferrigno, Francesco Fusco, Giovanna Viruses Brief Report There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations. MDPI 2022-03-21 /pmc/articles/PMC8950724/ /pubmed/35337057 http://dx.doi.org/10.3390/v14030650 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Cicchitto, Gaetano Cardillo, Lorena de Martinis, Claudio Sabatini, Paola Marchitiello, Rosita Abate, Giovanna Rovetti, Adele Cavallera, Antonietta Apuzzo, Camillo Ferrigno, Francesco Fusco, Giovanna Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title | Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title_full | Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title_fullStr | Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title_full_unstemmed | Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title_short | Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant |
title_sort | effects of casirivimab/imdevimab monoclonal antibody treatment among vaccinated patients infected by sars-cov-2 delta variant |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950724/ https://www.ncbi.nlm.nih.gov/pubmed/35337057 http://dx.doi.org/10.3390/v14030650 |
work_keys_str_mv | AT cicchittogaetano effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT cardillolorena effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT demartinisclaudio effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT sabatinipaola effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT marchitiellorosita effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT abategiovanna effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT rovettiadele effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT cavalleraantonietta effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT apuzzocamillo effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT ferrignofrancesco effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant AT fuscogiovanna effectsofcasirivimabimdevimabmonoclonalantibodytreatmentamongvaccinatedpatientsinfectedbysarscov2deltavariant |